Page last updated: 2024-11-02

pioglitazone and Chromosome-Defective Micronuclei

pioglitazone has been researched along with Chromosome-Defective Micronuclei in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Pioglitazone (PTZ) is an oral antidiabetic agent whose anti-cancer properties have been described recently."1.43Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay. ( de Castro-Prado, MA; Franco, CC; Mathias, PC; Morais, JF; Pereira, TS; Sant'Anna, JR, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oz Gul, O1
Cinkilic, N1
Gul, CB1
Cander, S1
Vatan, O1
Ersoy, C1
Yılmaz, D1
Tuncel, E1
Morais, JF1
Sant'Anna, JR1
Pereira, TS1
Franco, CC1
Mathias, PC1
de Castro-Prado, MA1

Other Studies

2 other studies available for pioglitazone and Chromosome-Defective Micronuclei

ArticleYear
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
    Mutation research, 2013, Sep-18, Volume: 757, Issue:1

    Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem

2013
Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay.
    Mutagenesis, 2016, Volume: 31, Issue:4

    Topics: Aspergillus nidulans; Cells, Cultured; DNA; DNA Damage; Humans; Hypoglycemic Agents; Loss of Heteroz

2016